November 15, 2021 7:36am
Is there any upside for the sector stock holders? It’s coming slowly, waiting for news to affect sentiment
Pre-open indications: 3 SELLs, 6 BUYs and 1 Pump (or No Promote)
Earnings: Athersys (ATHX), Brainstorm Cell Therapeutics (BCLI) and Homology Medicine (FIXX)
What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
Remember that overnight and pre-open actions in futures doesn't necessarily translate into actual trading in the coming day’s session.
Dow futures are UP +0.30% (+108 points), S&P futures are UP +0.22% (+10 points) and NASDAQ futures are UP +0.21% (+34 points)
U.S. stock futures were up yet, weak and slipping in early morning trading on Monday
European markets were flat,
Asia-Pacific markets were mixed.
Henry’omics:
The stock market rally ending with a a down week as inflation data sparked a questioning of fair value and the stem, cell and gene therapy sector nicked its seventh (7th) session decline
After Friday, the Nasdaq is 5% above its 50-day line with the Nasdaq 100 5.2%. It wouldn't take much to see those indexes back above the 6% level that suggests another pullback is growing likely. Ideally, the major indexes could continue to move sideways, letting leading stocks form handles, carve bases or find support at their key moving averages. (IBD)
If you didn’t remember what happen at Friday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:
Friday’s evening’s recap: “gravity is more than a force, it’s a sector disorder. I used to think negativity was a state of mind. Now, having watched for long enough, I come to realize negativity can be a character trait.” … https://www.regmedinvestors.com/articles/12182
Q4: November, 3 positive and 7 negative close to date
- October, 8 positive and 13 negative closes
Companies in my headlights – It’s your decision; I provide an idea and context:
Maintaining SELL with a Pump or No Promote:
Biostage (BSTG) closed FLAT AT $2.60 with 0 shares traded after Thursday’s -$0.22 to $2.60 with 2,005 shares traded after Wednesday’s +$0.18 with 2,006 shares traded after Tuesday’s -$0.03 with 3,304 shares traded, Monday’s +$0.07 with 7,082 shares traded after being down -$0.60
What’s there to invest in – the “Sword of Damocles” hanging over its recent insurance company rejection of legal expense/costs of a terminal death suit against the company?
- For a company with NO clinical trial, an a one (1) and a half year approved IND, four (4) employees and NO CRO <clinical research organization> initiation.
Probabilities versus aftermarket/pre-open share pricing indication moves:
Maintaining SELL into Strength:
Chinook Therapeutics (KDNY) closed up +$0.38 to $16.46 after Thursday’s +$0.10 to $16.08, Wednesday’s +$1.47 to $15.98, Tuesday’s +$0.32 to $14.51 and Monday’s -$1.77 with NO pre-market indication after executing an up-sized offering. Watch for the flipping post offering …
BUY:
Applied Genetic Technologies (AGTC) closed up +$0.11 to $2.60 with a positive +$0.10 or +3.85% pre-open indication after earnings release and in the non-randomized, open-label study, secondary outcome measures of clinical activity were observed through functional improvements in treated versus untreated control eyes. Treatment with AGTC-501 resulted in a statistically significant improvement in best-corrected visual acuity (BCVA) across all treatment groups (n=20) in patients where the macula was treated.
BioLife Solutions (BLFS) closed down AGAIN -$2.15 to $46.55 after Thursday’s -$0.81 TO $48.80 after Wednesday’s -$3.90 to $49.61, Tuesday’s +$0.28 to $53.51, Monday’s -$0.59 and last Friday’s -$4.73 with a positive +$0.28 or +0.60% pre-market indication.
CRISPR Therapeutics (CRSP) closed up +$1.01 to $88.93 after Thursday’s +$0.34 to $87.92 with a positive +$0.07 or +0.08% aftermarket indication.
Intellia Therapeutics (NTLA) closed up +$1.73 to $132.23 after Thursday’s+$3.72 to $130.50, Wednesday’s -$11.58 to $126.78, Tuesday’s +$2.29 to $138.36 and Monday’s +$0.59 to $136.07 with a positive +$0.67 or +0.51% pre-open indication.
Mesoblast (MESO) closed up +$0.20 to $6.27 and has a positive +$0.93 or +14.93% pre-open indication on news of results from the randomized, controlled Phase 3 trial of rexlemestrocel-L in 565 patients with New York Heart Association (NYHA) class II and class III chronic heart failure (CHF) with reduced ejection fraction (HFrEF). Bottom Line … A single dose of rexlemestrocel-L on top of standard of care reduced the incidence of heart attacks or strokes by 65% across all 537 NYHA class II or class III treated patients compared with standard of care
Pluristem (PSTI) closed down -$0.10 to $2.81 and has a positive +$0.03 or +1.06% pre-open indication on news of that its multinational P3 multicenter, randomized, double-blind, placebo-controlled study, designed to determine the efficacy, safety, and tolerability of intramuscular administration of allogeneic PLX-PAD cells for the treatment of muscle injury following arthroplasty for hip fracture is fully enrolled with 240 patients.
SELL into Strength:
Verastem (VSTM) closed up +$0.21 to $3.14 after Thursdays +$0.28 to $2.93 and has NO pre-market indication.
SELL:
Editas Medicine (EDIT) closed down -$0.30 to $37.90 after Thursday’s +$0.31 to $38.20 after Wednesday’s -$2.67 to $37.89, Tuesday’s -$0.01 to $40.56, Monday’s +$3.07 to $40.57 with a negative pre-market of -$0.20 or -0.53%.
The BOTTOM LINE: As I ask again, “is there a bounce after a trounce and how many?”
The Nasdaq and especially the Nasdaq 100 had been getting a little extended themselves, with the S&P 500 and Russell 2000 getting close to some warning areas. After Friday's bounce, the Nasdaq is 5% above its 50-day line with the Nasdaq 100 5.2%. It wouldn't take much to see those indexes back above the 6% level that suggests another pullback is growing likely. <IBD>
I am still manning the bully pulpit, expressing the theme of “Reducing exposure as well as being patient in your willingness to stay fully invested, I’d been recommending very careful buy-ins for the hopes of gains through the month and year-end.
We are seeing to date, two (2) net income – Bellicum Pharmaceuticals (BLCM) and BioLife Solutions (BLFS)
- Twenty-one (21) net losses to date <uniQure (QURE), Alnylam Pharmaceuticals (ALNY), Regenxbio (RGNX), Sage Therapeutics SAGE), Ultragenyx Pharmaceuticals (RARE), Voyager Therapeutics (VYGR), Solid Biosciences (SLDB), Ionis Pharmaceuticals (IONS), CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), Caladrius Biosciences (CLBS), AxoGen (AXGN), Adverum Biotechnologies (ADVM), Verastem (VSTM), Global Blood Therapeutics (GBT), Fate Therapeutics (FATE), Sangamo Therapeutics (SGMO), Cellectis SA (CLLS), Editas Medicine (EDIT) and today’s … Applied Genetic Technologies (AGTC) and Vericel (VCEL)>
… Earning’s releases that initiated Q3 earnings reporting season and beginning the tug-of-war between share pricing that is softer than usual and the usual LPS (loss-per-share) to be less than estimates and expectations.
The stem, cell and gene therapy earnings continue with coming 11/15 (to date with more coming).
I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
